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Abstract
Objective
The purpose of this review of literature is to evaluate the effects of cinnamon on hemoglobin A1C (HbA1c) and fasting blood
glucose/fasting plasma glucose (FBG/FPG) in various populations such as type II diabetes, prediabetics, metabolic syndrome, and
overweight or obese individuals.
Research Design and Methods
A comprehensive literature review was done with the Cumulative Index to Nursing and Allied Health Literature (CINAHL)
database using the keywords, cinnamon, type II diabetes, diabetes, HbA1c, and FBS. References used in previous meta-analysis were
also searched and reviewed for inclusion. Studies were included in this review if they evaluated cinnamon effects on HbA1c and/or
FBS/FPG. A total of 15 trials were incorporated in this literature review, 10 studied cinnamon’s effect on HbA1c levels and 13
studied cinnamon’s effect on the FBG.
Results
Six trials showed significant reductions in the HbA1c levels and 10 trials showed significant reductions in the FBG.
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Conclusion
Based on this review of literature, cinnamon can be recommended as effective therapy for reducing HbA1c levels and FBG
levels in type II diabetics. To reduce FBG and HbA1c levels, cinnamon can be dosed at 1 g to 6 g daily with meals (i.e. one to four
500 mg tablets BID or TID with meals).
Cinnamon in the Treatment of Type II Diabetes
Diabetes affects people of all races, ethnicities, ages, and genders and can significantly alter quality of life, especially when not
well controlled. Conditions such as metabolic syndrome and prediabetes often result in diabetes within a few years. Controlling these
syndromes and diabetes becomes a dilemma when it is coupled with the cost of medications, for those with health insurance as well as
for those without. The United States Census Bureau stated that 42 million Americans did not have health insurance in 2013 (Smith &
Medalia, 2014). These individuals have the full burden of paying for their own health care costs. The average cost of diabetic
medications, supplies, and provider appointments, etc., is estimated at $13,700 per year (American Diabetes Association, 2015).
Individuals suffering from the aforementioned prediabetic conditions and diabetes are often started on medications such as Metformin,
and are seen quarterly by their providers; therefore, have increasing medical expenses as well. Piette, Heisler, and Wagner (2004)
stated, “Out-of-pocket medication costs pose a significant burden to many adults with diabetes” (p. 384). As a result, 20% of diabetic
patients forgo taking their medications, as prescribed, in an effort to reduce their out-of-pocket expenses (Piette, Heisler, & Wagner,

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

4

2004). If diabetes is not well controlled, the long term effects can be costly, as well as deadly, as diabetes can lead to comorbidities
such as neuropathy, retinopathy, nephropathy, hypertension, dermatological problems, and amputations, etc. It is imperative that
prediabetic states and diabetes be well controlled to improve the quality of life within these disease processes, and to reduce the long
term cost of comorbidities associated with these illnesses. New cost effective alternatives, such as cinnamon supplementation, need to
be identified to help reduce long term side effects and the out-of-pocket expenses for prediabetic states and diabetes.
Cinnamon has been widely used for decades as a dietary supplement for diabetes, especially in other countries like China, and
there is increased awareness in the area of natural or alternative supplements in the United States due to costs and side effects
associated with traditional pharmaceuticals, even though the Food and Drug Administration (FDA) does not regulate or manage the
manufacturing of herbal remedies. Shane-McWhorter (2013) found that 67% of diabetics used herbal supplements such as cinnamon
to lower their blood glucose levels, which may imply a desire to self treat their diabetes. Lu et al. (2012) found that “cinnamon
supplementation is able to significantly improve blood glucose control in Chinese patients with type 2 diabetes” (p. 1). Cinnamon has
been shown to reduce insulin resistance, reduce blood glucose and lipid levels, reduce inflammation, and increase antioxidant activity
(Qin, Panicker, & Anderson, 2010). Despite these benefits and wide spread use of cinnamon and other natural supplements, most
traditional providers in the United States do not prescribe or recommend cinnamon or other natural supplements. This may be due to
the lack of regulation and approval by the FDA and the lack of evidence of efficacy, or may be due to their own belief or perceptions
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about cinnamon and other natural supplements. Whatever the reason, there may not be enough information to influence providers to
act. Increased studies that show support for cinnamon use in the treatment of type II diabetes, metabolic syndrome, and prediabetes
may be the cue to action that is needed.
There are only a handful of studies that have been done on the effects of cinnamon in the treatment of type II diabetes and not
all show positive results. A few studies have been done on the effects of cinnamon on other disease processes as well as healthy
individuals. Wang et al. (2007) studied the effects of cinnamon on women with PCOS. Results showed significant reductions in
insulin resistance in the cinnamon group but not in the placebo group. Solomon and Blannin (2007 & 2009) examined the effects of
cinnamon on healthy individuals using OGTT. Their trails showed that cinnamon 5 g and 3 g, respectively, can reduce glucose
responses to OGTT and improve insulin sensitivity in healthy individuals. Hlebowicz, Darwiche, Björgell, and Almér (2007) and
Hlebowicz et al. (2009) also show the efficacy of cinnamon in healthy individuals on postprandial blood glucose, gastric emptying,
satiety, serum insulin, GLP-1 concentrations, GIP, gherlin, and GER. Prior meta-analysis have focused primarily on the type II
diabetic population or have excluded studies that did not report specific biochemical markers like fasting blood sugar (FBS) (Davis &
Yokoyama, 2011). There is a need for a more comprehensive review of the effects of cinnamon on multiple biochemical measures as
well as multiple disease processes. The purpose of this review of literature is to evaluate the effects of cinnamon on hemoglobin A1C
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(HbA1c) and fasting blood glucose/fasting plasma glucose (FBG/FPG) in various populations such as type II diabetes, prediabetics,
metabolic syndrome, and overweight or obese individuals.
Theoretical Framework
The theoretical framework utilized for this research proposal is the Health Belief Model applied mostly from the perspective of
the provider. This model theorizes that belief and perceptions influence actions (Glanz, & Rimer, 2005). The researcher has predicted
that there is a relationship between cinnamon therapy and reduction of some biochemical measures; however, providers do not
currently prescribe or recommend its use.
The Health Belief Model describes how modifiable variables and perceived ideas such as severity of consequences,
susceptibility, benefits versus barriers, and cues to action can bring about the likelihood of engaging in actions that can promote health
(Glanz, & Rimer, 2005). Providers are aware of the susceptibility and severity of type II diabetes. They can be educated about the
perceived benefits of cinnamon, i.e., efficacy in lowering HbA1c levels and blood glucose levels, low cost, and no side effects (unless
there is an allergy to cinnamon). The perceived barriers to prescribing cinnamon are the lack of FDA regulation of cinnamon, lack of
recommendation by the American Diabetic Association (ADA), lack of knowledge of the efficacy of cinnamon in lowering some
biochemical measurements, and presumed lack of research to support its use. Cues to actions may be evidence-based trials that show
benefits and effectiveness of cinnamon in the treatment of type II diabetes and other disease states, while reducing variables such as
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the dosing amount of cinnamon. With knowledge of such trials, primary care providers may be influenced to act and prescribe this
supplement. Providers, therefore, will be promoting health and self sufficiency in their patients, as their patients will be less
dependent on multiple medications, have fewer medication-induced side effects, and fewer medication-induced medical problems.
Materials and Methods
A comprehensive literature review was done with the Cumulative Index to Nursing and Allied Health Literature (CINAHL)
database using the keywords, cinnamon, type II diabetes, diabetes, HbA1c, and FBS. References used in previous meta-analysis were
also searched and reviewed for inclusion. Studies were included in this review if they evaluated cinnamon effects on HbA1c and/or
FBS/FPG. Studies on type I diabetes were excluded because type I diabetics have a deficiency of insulin rather than insulin
resistance, and this literature review is focusing on insulin resistance. Another study excluded was done by Wainstein et al. (2011) on
type 2 diabetics because the cinnamon tablet contained cinnamon, zinc gluconate and tri-calcium phosphate. Also not included in this
review were studies done on rats.
A total of 15 trials were incorporated in this literature review. Thirteen of the trials studied the effects of cinnamon on type II
diabetic participants, one trial assessed the effects of cinnamon on prediabetic and metabolic syndrome individuals, and one trial
studied the efficacy of cinnamon use in overweight or obese individuals. Of these trials, 10 measured HbA1c levels and 13 measured
FBG. Other biochemical markers were measured but are not part of this review.
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Results
HbA1c
The HbA1c level measures the average blood sugars over a three month period, and is important in diabetic management
because higher HbA1c levels denote greater risk of developing diabetes-related complications. Crawford (2009) studied whether 1
gram of cinnamon cassia taken daily for 90 days would lower HbA1c levels in poorly controlled type II diabetes. Cinnamon 1 g daily
was found to have lowered HbA1c levels by 0.83% (P < 0.001). Usual care alone without cinnamon, lowered the HbA1c 0.37% (P <
0.16). Crawford concluded that cinnamon does lower HbA1c for this population. Lu et al. (2012) also studied the effect of cinnamon
on HbA1c levels for participants with type II diabetes. Cinnamon extract prepared from the bark of Chinese Cinnamomum
aromaticum was used. In this study, they compared a placebo, low dose cinnamon (120mg), and high dose cinnamon (360mg). The
cinnamon or placebo tablets were taken every morning before breakfast for three months. After three months, they found that for
those in the low dose group, their HbA1c was reduced an average of 0.67% (8.90 + 1.24 to 8.23 + 0.99), (P = .003), and in the high
dose group an average of 0.92% (8.92 + 1.35 to 8.00 + 1.00), (P = 0.0004). In this study, the higher dose was more effective than the
lower dose.
The effect of cinnamon supplementation was again studied by Sharma, Sharma, Agrawal, Agrawal, and Singhal (2012) in
newly diagnosed type II diabetics. One hundred fifty newly diagnosed type II diabetics were stabilized with diet and exercise for one
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month prior to beginning the cinnamon supplementation. The participants were randomized into: a 3 g cinnamon group, a 6 g
cinnamon group, a placebo group. After three months, it was found that for the 3 g group (taking 1 g after each meal) the HbA1c went
from 8.47 +/- 1.02 at baseline to 7.29 +/- 0.83 post intervention, p < 0.005. In the 6 g group (taking 2 g after each meal), the HbA1c
went from 8.10 +/- 0.84 at baseline to 7.25 +/- 0.81 post intervention, p < 0.005. Both doses had equivalent efficacy. Vafa et al.
(2012) treated type II diabetes with Cinnamomum zeylanicum. Participants took two 500 mg tablets of Cinnamomum zeylanicum at
each main meal for eight weeks, for a total of 3 grams daily. The researchers concluded that cinnamon significantly decreased HbA1c
(P = 0.008), of the treatment group, compared to the placebo group. It is noted that even though the HbA1c levels of these participants
were well controlled at baseline (7.35 + 0.51) the Cinnamomum zeylanicum was still effective in significantly reducing the mean level
overall.
Al-Yasiry, Kathum, and Al-Ganimi (2014) studied the hypoglycemic effect of cinnamon on 40 poorly controlled male type II
diabetics. The participants were given 0.5 g of ground crude cinnamon 15 minutes after each meal for a total of 1.5 g daily for three
months. They found that using 1.5g of ground cinnamon daily decreased the HbA1c which went from 9.54 + 0.96 pretreatment to
8.22 + 0.65 post treatment, (P < 0.01).
Cinnamon cassia usage in type II diabetics was studied by Akilen, Tsiami, Devendra, Robinson (2010). Participants were
given one 500 mg tablet of cinnamon cassia with breakfast and dinner and two 500 mg tablets with lunch, for a total of 2 g daily. The
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ingestion of 2 g of cinnamon each day was found to significantly reduce the HbA1c level, 8.22 + 1.16 to 7.86 + 1.42, p < 0.05. A
moderate positive correlation was found between the baseline HbA1c level and the significant drop of the HbA1c level suggesting that
cinnamon supplementation for poorly controlled diabetics may play a positive role in managing their disease, r = 0.567, P = 0.008.
Four studies found no significant difference in the HbA1c levels with the use of cinnamon. Vanschoonbeek, Thomassen,
Senden, Wodzig, and van Loon (2006) investigated the effects of 1.5 g per day of cinnamon cassia on HbA1c levels of 25
postmenopausal women with well controlled type II diabetes over a six week time frame. No significant changes were found. It must
be noted that an appropriate amount of time was not given for a change to be properly noted in the HbA1c level as this trial was done
over six weeks instead of three months. Blevins, Leyva, Brown, Wright, Scofield, and Aston (2007) also showed no significant results
of cinnamon on HbA1c levels. For three months, cinnamon cassia 1 g was given daily. It was found that this dosage of cinnamon
given daily for three months produced no significant change in HbA1c levels (P > 0.05). Mang et al. (2006) studied the effects of 3 g
cinnamon daily on 79 type II diabetics over 4 months. Their study showed no significant decrease in the HbA1c levels post
treatment. Suppapitiporn and Kanpaksi (2006) examined the efficacy of cinnamon cassia 1.5 g daily on reducing the HbA1c levels of
60 type II diabetics. After 12 weeks of intervention, it was found that the HbA1c levels decreased in both the placebo group and the
cinnamon group. There was a greater reduction of the HbA1c level in the cinnamon group, and more patients in the cinnamon group
achieved a HbA1c level of < 7% as compared to the placebo group; however, the reductions were not statistically different, p > 0.05.
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The participants in the Vanschoonbeek et al., 2006 trial, the Blevins et al., 2007 trial, and the Mang et al., 2006 trial were all
well controlled diabetics with baseline HbA1c levels of 6.86 to 7.4. DeFronzo, Stonehouse, Han, and Wintle (2010) did a metaanalysis of 59 trials with a total of 8479 patients on the relationship of baseline HbA1c levels and the effectiveness of 10 different
classes of hyperglycemic medications and produced a weighted R2 of 0.35 (P < 0.0001). These results show a positive correlation
between the baseline HbA1c levels and magnitude of change of the HbA1c level after treatment with glucose-reducing therapies
regardless of drug classification. They further state that “These observations should be considered when assessing clinical efficacy of
diabetes therapies derived from clinical trials, particularly when evaluating data from clinical trials of patients with relatively low
baseline HbA1c levels, 7.0 – 8.0% (DeFronzo, Stonehouse, Han, & Wintle, 2010, p.309, 314).” Lower baseline HbA1c levels prior to
intervention produce smaller and less significant changes in the HbA1c levels post intervention.
FBG/FPG
The most common test used to diagnose diabetes is the fasting blood glucose level. This test is more definitive than random
blood glucose tests because it measures the blood glucose level after a period of at least eight hours of fasting (no food or liquids
except water) eliminating the chance that the results have been influenced by recent food or beverage intake (OneTouch, no date).
Khan, Safdar, Ali Khan, Khattak, and Anderson (2003) conducted the first in vivo study on the use of cinnamon in improving FBG
levels. Cinnamon cassia was given 1 g daily as one 500 mg table taken at lunch and dinner, 3 g daily as two 500 mg tablets taken at
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breakfast, lunch, and dinner, or 6 g daily as four tablets taken at breakfast, lunch, and dinner. The researchers found that all three
doses of cinnamon reduced the mean FBG serum levels (18-29%, P < 0.05) of the participants in the treatment groups after 20, 40, and
60 days.
Anderson et al. (2010) studied the effects of cinnamon cassia 250 mg given twice a day to participants with type II diabetes.
After two months it was found that the FBS decreased from 8.85 + 0.32 pretreatment to 8.19 + 0.29 mmol/L post treatment, p < 0.001.
Mang et al. (2006) evaluated the usage of cinnamon cassia 1 g daily for type II diabetics. Participants took the cinnamon as prescribed
for four months. The cinnamon group was found to have a significant reduction in the FBG between baseline and post intervention
levels (9.26 + 2.26 to 8.15 + 1.65 mmol/L, p < 0.001). Ziegenfuss, Hofheins, Mendel, Landis, and Anderson (2006) evaluated the
effects of Cinnulin PF 500 mg once a day (which is equivalent to 10 g whole cinnamon powder) on the FBG of prediabetic and
metabolic syndrome participants. After 12 weeks, the FBG levels decreased – 8.4% from 116.3 + 12.8 mg/dl to 106.5 + 20.1 mg/dL,
p < 0.01. The efficacy of Cinnulin PF was also studied by Roussel, Hininger, Benaraba, Ziegenfuss, and Anderson (2009) in reducing
the FBG of overweight or obese subjects. Cinnulin PF 250 mg was taken twice a day for 12 weeks. The FBG dropped from 114 + 2.2
to 102 + 4.3 mg/dL, p < 0.05, between pre and post treatment with Cinnulin PF. Khan, Khan, and Shah (2010) studied the effects of
1.5 g of ground cinnamon 1.5 g on the FBG of type II diabetic participants. For 30 days the participants ingested 0.5 g of cinnamon
three times a day with meals. A significant reduction of the FBG was found with the use of cinnamon (216.3 + 52.7 to 163.3 + 44.9
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mg/dL, p < 0.05). In a three month trial, Lu et al. examined the efficacy of cinnamon cassia 120 mg and 360 mg daily in reducing the
FBS in 60 Chinese participants who were type II diabetics. Results showed a statistically significant decrease in both groups.
Baseline FBG levels decrease from 9.00 to 7.99 mmol/L in the 120 mg group, and from 11.21 to 9.59 mmol/L in the 360 mg group, (P
= 0.00008).
The effects if cinnamon in newly diagnosed type II diabetics was studied by Sharma, Sharma, Agrawal, Agrawal, and Singhal
(2012). One hundred and fifty participants were divided into three groups and given a placebo, 3 g cinnamon, or 6 g cinnamon daily
spread out over three meals. FBG levels were drastically reduced in both cinnamon groups. Baseline FBG levels decreased 49% in
the 3 g cinnamon group from 226.73 + 21.43 to 115.5 + 23.03, and 48% in the 6 g cinnamon group from 216.94 + 26.27 to 112.26 +
22.85, (p < 0.001). The effectiveness of Cinnamomum zeylanicum in the reduction of FBG was assessed by Vafa et al. (2012). Two
500 mg tablets were given to 37 subjects three times daily for eight weeks. Cinnamomum zeylanicum, also known as true cinnamon,
significantly reduced the FBG in the cinnamon group 139.28 + 9.11 to 126.47 + 17.73, (P < 0.05). Al-Yasiry, Kathum, and AlGanimi (2014) determined the hypoglycemic effects of cinnamon on 40 poorly controlled male type II diabetics. Participants were
given 1.5 g cinnamon daily for 3 months. Cinnamon cassia produced a 27.5% decline in the FBG of the participants, 174.70 + 19.83
to 126.25 + 17.85, (P < 0.01).
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In contrast, some trials found no significant reduction in FBG levels after cinnamon supplementation. Vanschoonbeek,
Thomassen, Senden, Wodzig, and van Loon (2006) investigated the effects of cinnamon 1.5 g on FBG levels of 25 postmenopausal
women with well controlled type II diabetes over six weeks. Although there was some decline of the FBG in the cinnamon group,
8.37 + 0.59 to 7.91 + 0.71, it was not statistically significant, (P > 0.05). Suppapitiporn and Kanpaks (2006) evaluated the effects of
cinnamon cassia 1.5 g daily, taken over 12 weeks, on type II diabetics. No statistical significance was found in the FBG.
Blevins et al. (2007) explored the effects of 1 g cinnamon cassia on 57 non-insulin dependent type II diabetics. After a three month
intervention phase, no significant change was noted in the FBG.
Discussion and Implications for Practice
The global prevalence of diabetes was estimated at 9% in 2014 in individuals 18 and over. That is over 350 million people
worldwide (World Health Organization, no date) (WHO). Diabetes significantly affects quality of life and leads to death when not
well controlled. Over 3 million people die of diabetes and its comorbidities yearly. Centers for Disease Control and Prevention
(2014a, 2014b)(CDC) states that diabetes was the 7th leading cause of death in 2010. The American Diabetic Association estimates
the cost of diabetes at $13,700 yearly per person, making diabetes costly as well as deadly. Controlling diabetes and its predecessor
diseases, prediabetes and metabolic syndrome is imperative to improving the health of our country and reducing health care
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expenditures. Finding safe, efficacious, and cost effective alternative treatments for diabetes is a must. Cinnamon is a promising
alternative treatment that has been used for decades as a dietary supplement for diabetes.
Based on this review of literature, cinnamon can be recommended as effective therapy for reducing HbA1c levels and FBG
levels in type II diabetics. Cinnamon was also found to be effective in lowering FBG levels in prediabetics, overweight and obese
individuals. Cinnamon cassia, Cinnamomum zeylanicum, and Cinnulin PF have been shown to have similar efficacy in these
populations; however, Cinnamomum zeylanicum may be more advantageous when diabetes is more controlled (Akilen, Tsiami,
Devendra, and Robinson, 2010). This review of literature recommends cinnamon as an efficacious and cost effective treatment of
uncontrolled type II diabetes which may potentially have some cardiovascular benefits. To reduce FBG and HbA1c levels, cinnamon
can be dosed at 1 g to 6 g daily with meals (i.e. one to four 500 mg tablets BID or TID with meals). No adverse effects were seen with
any of the cinnamon doses. Patients should be watched for cinnamon allergies, although none were reported in any of the studies
reviewed.
Conclusion
Further research needs to be done to evaluate if cinnamon is as equally effective in reducing the HbA1c level and FBG level in
the stable type II diabetic (HbA1c level < 8.0 or FBG < 183) versus the unstable type II diabetic (HbA1c > 8.0 or FBG > 183, as well
as the effectiveness of various types of cinnamon such as, cinnamon cassia, Cinnamomum zeylanicum, and Cinnulin PF.

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

16

References
Akilen, R., Tsiami, A., Devendra, D., & Robinson, N. (2010). Glycated haemoglobin and blood pressure‐lowering effect of
cinnamon in multi‐ethnic Type 2 diabetic patients in the UK: a randomized, placebo‐controlled, double‐blind clinical trial.
Diabetic Medicine, 27(10),1159-1167.
Al-Yasiry, K., Kathum, W., & Al-Ganimi, Y. (2014). Evaluation of Anti-Diabetic Effect of Cinnamon in Patients with Diabetes
Mellitus Type Ii in Kerbala City. Journal of Natural Sciences Research, 4(4), 43-45
American Diabetes Association. (2014). Statistics about diabetes. Retrieved from http://www.diabetes.org/diabetesbasics/statistics/?loc=superfooter
American Diabetes Association. (2015). The cost of diabetes. Retrieved from http://www.diabetes.org/advocacy/news-events/cost-ofdiabetes.html
Anderson, R. A., Zhan, Z., Luo, R., Guo, X., Guo, Q., Zhou, J., . . . Stoecker, B. J. (2010). Cinnamon extract lowers glucose, insulin
and cholesterol in people with elevated serum glucose. Journal of Traditional and Complementary Medicine, doi:
10.1016/jtcme.2015.03.005
Blevins, S. M., Leyva, M. J., Brown, J., Wright, J., Scofield, R. H., & Aston, C. E. (2007). Effect of cinnamon on glucose and lipid

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

17

levels in non insulin-dependent type 2 diabetes. Diabetes Care, 30(9), 2236-2237. doi:dc07-0098 [pii]
Centers for Disease Control and Prevention. (2014a). 2014 national diabetes statistics report.Retrieved from
http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html
Centers for Disease Control and Prevention. (2014b). Diabetes latest. Retrieved from http://www.cdc.gov/features/diabetesfactsheet/
Crawford, P. (2009). Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: A randomized,
controlled trial. Journal of the American Board of Family Medicine : JABFM, 22(5), 507-512.
doi:10.3122/jabfm.2009.05.080093
Davis, P. A., & Yokoyama, W. (2011). Cinnamon intake lowers fasting blood glucose: meta-analysis. Journal of medicinal food,
14(9), 884-889.
DeFronzo, R. A., Stonehouse, A. H., Han, J., & Wintle, M. E. (2010). Relationship of baseline HbA1c and efficacy of current
glucose‐lowering therapies: a meta‐analysis of randomized clinical trials. Diabetic medicine, 27(3), 309-317.
Hlebowicz, J., Darwiche, G., Björgell, O., & Almér, L. O. (2007). Effect of cinnamon on postprandial blood glucose, gastric
emptying, and satiety in healthy subjects. The American journal of clinical nutrition, 85(6), 1552-1556.
Hlebowicz, J., Hlebowicz, A., Lindstedt, S., Björgell, O., Höglund, P., Holst, J. J., ... & Almér, L. O. (2009). Effects of 1 and 3 g

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

18

cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide,
glucagon-like peptide 1, and ghrelin concentrations in healthy subjects. The American journal of clinical nutrition, 89(3), 815821.
Khan, A., Safdar, M., Ali Khan, M. M., Khattak, K. N., & Anderson, R. A. (2003). Cinnamon improves glucose and lipids of people
with type 2 diabetes. Diabetes Care, 26(12), 3215-3218.
Khan, R., Khan, Z., & Shah, S. (2010). Cinnamon may reduce glucose, lipid and cholesterol level in type 2 diabetic individuals.
Pakistan J Nutr, 9(5), 430-433.
Lu, T., Sheng, H., Wu, J., Cheng, Y., Zhu, J., & Chen, Y. (2012). Cinnamon extract improves fasting blood glucose and glycosylated
hemoglobin level in Chinese patients with type 2 diabetes. Nutrition Research (New York, N.Y.), 32(6), 408-412.
doi:10.1016/j.nutres.2012.05.003.
Mang, B., Wolters, M., Schmitt, B., Kelb, K., Lichtinghagen, R., Stichtenoth, D. O., & Hahn, A. (2006). Effects of a cinnamon extract
on plasma glucose, HbA1c, and serum lipids in diabetes mellitus type 2. European journal of clinical investigation, 36(5), 340344.
National Diabetes Education Initiative. (2015). Diabetes management Guidelines. Retrieved from http://www.ndei.org/ADA-diabetesmanagement-guidelines-glycemic-targets-A1C PG.aspx

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

19

OneTouch. (no date). Fasting blood glucose test. Retrieved from http://www.onetouch.com/articles/fasting-blood-glucose-test
Piette, J. D., Heisler, M., & Wagner, T. H. (2004). Problems paying out-of-pocket medication costs among older adults with diabetes.
Diabetes Care, 27(2), 384-391.
Qin, B., Panickar, K. S., & Anderson, R. A. (2010). Cinnamon: Potential role in the prevention of insulin resistance, metabolic
syndrome, and type 2 diabetes. Journal of Diabetes Science and Technology, 4(3), 685-693. Retrieved from
https://ezproxy.southern.edu/login?url=http://search.ebscohost.com/login.aspx?direct=tru
e&db=cmedm&AN=20513336&site=eds-live
Roussel, A. M., Hininger, I., Benaraba, R., Ziegenfuss, T. N., & Anderson, R. A. (2009). Antioxidant effects of a cinnamon extract in
people with impaired fasting glucose that are overweight or obese. Journal of the American College of Nutrition, 28(1), 16-21.
Shane-McWhorter, L. (2013). Dietary supplements for diabetes are decidedly popular: help your patients decide. Diabetes Spectrum,
26(4), 259-266.
Sharma, P., Sharma, S., Agrawal, R., P., Agrawal, V., & Singhal, S. (2012). A randomised double blind placebo control trial of
cinnamon supplementation on glycemic control and lipid profile in type 2 diabetes mellitus. Australian Journal of Herbal
Medicine, 24(1), 4-9. Retrieved from

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

20

https://ezproxy.southern.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=2011688521&site=
ehost-live&scope=site
Smith, J. C., & Medalia, C. (2014). Health insurance coverage in the United States: 2013 US Department of Commerce, Economics
and Statistics Administration, Bureau of the Census.
Solomon, T. P. J., & Blannin, A. K. (2007). Effects of short‐term cinnamon ingestion on in vivo glucose tolerance. Diabetes, Obesity
and Metabolism, 9(6), 895-901.
Solomon, T. P., & Blannin, A. K. (2009). Changes in glucose tolerance and insulin sensitivity following 2 weeks of daily cinnamon
ingestion in healthy humans. European journal of applied physiology, 105(6), 969-976.
Suppapitiporn, S., & Kanpaksi, N. (2006). The effect of cinnamon cassia powder in type 2 diabetes mellitus. Journal of the Medical
Association of Thailand= Chotmaihetthangphaet, 89, S200-5.
Vafa, M., Mohammadi, F., Shidfar, F., Sormaghi, M. S., Heidari, I., Golestan, B., & Amiri, F. (2012). Effects of cinnamon
consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. International Journal of
Preventive Medicine, 3(8), 531.
Vanschoonbeek, K., Thomassen, B. J., Senden, J. M., Wodzig, W. K., & van Loon, L. J. (2006). Cinnamon supplementation does not
improve glycemic control in postmenopausal type 2 diabetes patients. The Journal of Nutrition, 136(4), 977-980.

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

21

doi:136/4/977 [pii]
Wang, J. G., Anderson, R. A., Graham, G. M., Chu, M. C., Sauer, M. V., Guarnaccia, M. M., & Lobo, R. A. (2007). The effect of
cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertility and sterility, 88(1),
240-243.
Wainstein, J., Stern, N., Heller, S., & Boaz, M. (2011). Dietary cinnamon supplementation and changes in systolic blood pressure in
subjects with type 2 diabetes. Journal of medicinal food, 14(12), 1505-1510.
World Health Organization. (no date). Diabetes. Retrieved from http://www.who.int/mediacentre/factsheets/fs312/en/
Ziegenfuss, T. N., Hofheins, J. E., Mendel, R. W., Landis, J., & Anderson, R. A. (2006). Effects of a water-soluble cinnamon extract
on body composition and features of the metabolic syndrome in pre-diabetic men and women. Journal of the International
Society of Sports Nutrition, 3(2), 45.

CINNAMON IN THE TREATMENT OF TYPE II DIABETES

22

Appendix A
Literature Review Matrix
Needs to be
full reference
1. Khan, A.,
Safdar, M.,
Ali Khan, M.
M., Khattak,
K. N., &
Anderson, R.
A. (2003).
Cinnamon
improves
glucose and
lipids of
people with
type 2
diabetes.
Diabetes
Care, 26(12),
3215-3218.

Purpose

Design

Independent

Dependent

The objective of this
study was to
determine whether
cinnamon improves
blood glucose,
triglyceride, total
cholesterol, HDL
cholesterol, and LDL
cholesterol levels in
people with type 2
diabetes.

Cinnamon cassia  FBG levels
one 500mg tablet  Lipid levels
taken at lunch
and dinner for 1g
dose.

2. Lu, T.,

We hypothesized

A total of 60 people
with type 2 diabetes,
were divided
randomly into six
groups. Groups 1, 2,
and 3 consumed 1,
3, or 6 g of
cinnamon daily,
respectively, and
groups 4, 5, and 6
were given placebo
capsules
corresponding to the
number of capsules
consumed for the
three levels of
cinnamon. The
cinnamon was
consumed for 40
days followed by a
20-day washout
period.
To address this

Cinnamon cassia
two 500mg
tablets taken at
breakfast, lunch
and dinner for 3g
dose.

Results
After 40 days, all three levels
of cinnamon reduced the
mean fasting serum glucose
(18–29%), triglyceride (23–
30%), LDL cholesterol (7–
27%), and total cholesterol
(12–26%) levels; no
significant changes were
noted in the placebo groups.
Changes in HDL cholesterol
were not significant.

Cinnamon cassia
four 500mg
tablets taken at
lunch and dinner
for 6 g dose.

Chinese adults >  HbA1c levels

Placebo group had no
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 FBG levels
 triglycerides
 HDL
 LDL
 total cholesterol
 liver
transaminase

Sheng, H.,
Wu, J.,
Cheng, Y.,
Zhu, J., &
Chen, Y.
(2012).
Cinnamon
extract
improves
fasting blood
glucose and
glycosylated
hemoglobin
level in
Chinese
patients with
type 2
diabetes.
Nutrition
Research
(New York,
N.Y.), 32(6),
408-412.
doi:10.1016/j
.nutres.2012.
05.003.

cinnamon should be
effective in
improving blood
glucose control in
Chinese patients with
type 2 diabetes. This
study was done to to
analyze the effect of
cinnamon extract on
glycosylated
hemoglobin A1c and
fasting blood glucose
levels.

hypothesis, we
performed a
randomized, doubleblinded clinical
study in Chinese
patients with type 2
diabetes. A total of
66 patients with type
2 diabetes were
recruited and
randomly divided
into 3 groups:
placebo and lowdose and high-dose
supplementation
with cinnamon
extract at 120 and
360 mg/d,
respectively.
Patients in all 3
groups took
gliclazide during the
entire 3 months of
the study.

age 48 with type
II diabetes.
Low dose
cinnamon
120mg.
High dose
cinnamon
360mg.
Cinnamon
extract tablets,
60 mg each,
prepared from
the bark of
Chinese
Cinnamomum
aromaticum

3. Crawford,
P. (2009).

Multiple trials in the
past have shown

109 type 2 diabetics
(HbA1C >7.0) were

Cinnamon
 HbA1c levels
Cassia 500 mg 2

significant change in pre &
post HA1C or FBG. Both the
HbA1c and FBG levels were
significantly reduced in post
treatment in the low and high
dose groups. HbA1c reduced
an average of 0.67% (P =
.003) in the low dose group
and reduced an average of
0.92% (P = 0.0004) in the
high dose group. The FBG
reduced an average of 1.10
mmol/L (P = .002)in the low
dose group and reduced an
average of 1.62 mmol/L (P =
.00008) in the high dose
group. Triglyceride levels
were reduced in the low dose
group (P = .007). Total
cholesterol, HDL, LDL, and
liver transaminases remained
unchanged in the 3 groups.

Cinnamon lowered HbA1c
0.83% (95% Cl, 0.46 - 1.20)
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Effectiveness
of cinnamon
for lowering
hemoglobin
A1C in
patients with
type 2
diabetes: A
randomized,
controlled
trial. Journal
of the
American
Board of
Family
Medicine :
JABFM,
22(5), 507512.
doi:10.3122/j
abfm.2009.0
5.080093

conflicting results of
whether cinnamon
lowers glucose or
hemoglobin A1C
(HbA1C). The
purpose of this study
was to determine
whether cinnamon
lowers HbA1C in
patients with type 2
diabetes. In this study
a randomized,
controlled trial was
performed to evaluate
whether daily
cinnamon plus usual
care versus usual care
alone lowers HbA1c.

4. Sharma,
P., Sharma,
S., Agrawal,

The aim of this study
was to evaluate
efficacy of cinnamon

randomized from 3
primary care clinics
caring for pediatric,
adult, and geriatric
patients at a United
States military base.
Participants were
randomly allocated
to either usual care
with management
changes by their
primary care
physician or usual
care with
management
changes plus
cinnamon capsules,
1g daily for 90 days.
HbA1c was drawn at
baseline and 90 days
and compared with
intention-to-treat
analysis. This study
was approved by an
institutional review
board.
One hundred and
fifty newly
diagnosed
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tabs daily
Usual diabetic
medications, no
placebo

 Cinnamon 1 g
 HbA1c levels
capsules at
 FBG levels
breakfast, lunch  SBP

(P < .001) compared with
usual care alone lowering
HbA1c 0.37% (95% Cl, 0.15 0.59) (P < .16).

After three months of
supplementation there was a
significant improvement in
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R., P.,
Agrawal, V.,
& Singhal, S.
(2012). A
randomized
double blind
placebo
control trial
of cinnamon
supplementat
ion on
glycemic
control and
lipid profile
in type 2
diabetes
mellitus.
Australian
Journal of
Herbal
Medicine,
24(1), 4-9.
Retrieved
from

supplementation on
blood sugar, HbA1c,
serum cholesterol,
triglyceride, LDL,
and HDL levels in
newly diagnosed type
2 diabetes mellitus
(T2DM).

individuals with
and dinner for
T2DM were selected 3g daily
randomly. After one  Cinnamon 2 g
month stabilization
capsules at
period, 150 patients
breakfast,
were divided into
lunch, and
three groups 1, 2,
dinner for 6g
and 3 given type A,
daily (Type B, C capsules
extract or cassia
blindly bearing
not specified)
distinctive code
 Time – 0, 1, and
number. All three
3 months
groups were also
 Conventional
given conventional
treatment of diet
treatment i.e. diet
and exercise
and exercise for 3
months.
Antropometric
parameters, blood
pressure, blood
sugar, HbA1c and
lipid profiles were
preformed initially
after 1 and 3 months
of treatment. After 3
months decoding
was done and
analyzed data by
ANOVA, t and r

25

 Cholesterol
 HDL
 LDL
 Triglycerides
 BMI

FBS and HbA1c in both
groups (3 gm FBS was 226.73
+/- 21.43 to 115.6 +/- 23.03, p
< 0.001, in HbA1c 8.47 +/1.02 to 7.29 +/- 0.83, p <
0.005, in 6 gm FBS was
216.94 +/- 26.27 to 112.26 +/22.85 and HbA1c was 8.10
+/- 0.84 to 7.25 +/- 0.81, p <
0.005). In BMI no significant
difference was observed.
There was a significant
difference in systolic blood
pressure (3 gm doses 130.75
+/- 14.10 to 126.60 +/- 13.16,
p < 0.005, and in 6 gm 126.8
+/- 13.73 to 121.65 +/- 11.34,
p < 0.001). In 3 gm doses
changes in cholesterol level,
LDL, triglyceride and HDL
were significant (190.16 +/25.19 to 164 +/- 17.82;
109.69 +/- 14.89 to 96.80 +/8.77; 213.5 +/- 40.14 to
146.04 +/- 38.34 and 40.148
+/- 6.16 to 45.43 +/- 0.27, p <
0.001, respectively). In 6 gm
cholesterol was 188.04 +/20.83 to154.31 +/- 17.94;
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irect=true&d
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2011688521
&site=ehostlive&scope=s
ite
5. Anderson,
R. A., Zhan,
Z., Luo, R.,
Guo, X.,
Guo, Q.,
Zhou, J., . . .
Stoecker, B.
J. (2010).
Cinnamon
extract
lowers
glucose,
insulin and
cholesterol in
people with
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test.

The purpose of this
study was to evaluate
the effects of
cinnamon on
circulating glucose,
lipids, insulin, and
insulin resistance in
the Chinese
population.

A total of 137
 Cinnamon
Chinese participants
cassia water
with type 2 diabetes
dried extract
were randomly
250 mg BID for
assigned to two
a total of 500
groups in this double mg for 2
blind placebomonths
controlled trial. The  100 g of white
cinnamon group
steamed bread
took one 250 mg
(equivalent to
cinnamon capsule
75 g of
BID for a total of
carbohydrate)
500 mg. The control
group received
placebo capsules

LDL 102.51 +/- 21.70 to
90.85 +/- 19.10; triglyceride
206.50 +/- 72.50 to147.28 +/51.29 and HDL was 43.73 +/11.77 to 69.78 +/- 8.66, p <
0.001.

 Fasting and 2
hour serum
blood glucose
 Insulin resistance
 Serum lipids
 Fructosamine
 SBP & DBP

After 2 mo, fasting glucose
decreased (p < 0.001) in the
cinnamon extractsupplemented group
(8.85 ± 0.36 to
8.19 ± 0.29 mmol/L)
compared with the placebo
group (8.57 ± 0.32 to
8.44 ± 0.34 mmol/L,
p = 0.45). Glucose 2 h after a
75 g carbohydrate load,
fasting insulin, and HOMAIR also decreased with
cinnamon extract compared
with placebo. Total and LDL-
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elevated
serum
glucose.
Journal of
Traditional
and
Complement
ary
Medicine,
doi:
10.1016/jtcm
e.2015.03.00
5

6. Vafa, M.,
Mohammadi,
F., Shidfar,
F., Sormaghi,
M. S.,
Heidari, I.,
Golestan, B.,
& Amiri, F.
(2012).
Effects of
cinnamon
consumption
on glycemic
status, lipid

The purpose of this
study was to evaluate
the effects of the
daily intake of three
grams cinnamon over
eight weeks on
glycemic status, lipid
profiles and body
composition in type 2
diabetic patients.
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which contained 250
mg of dark brown
(baked) wheat flour
and were very
similar in
appearance to the
cinnamon extract.

cholesterol decreased with
cinnamon extract and HDLcholesterol decreased in both
the cinnamon-extract and
placebo groups. In
conclusion, supplementation
with 500 mg of water-extract
of cinnamon for two months
reduced fasting insulin,
glucose, total cholesterol, and
LDL cholesterol and
enhanced insulin sensitivity of
subjects with elevated blood
glucose.

A double blind,
 Cinnamon
 FBG levels
randomized, placebo zeylanicum
 HbA1c
controlled,
(cinnamon
 Triglyceride
clinical trial was
verum or "true  Weight
conducted on 44
cinnamon") 500  BMI and body
patients with type 2
mg 2 tabs at
fat mass
diabetes.
each main meal
Participants were
daily for total of
randomly assigned
3 g daily for
to take either a three
eight weeks
g per
day cinnamon
supplement (n=22)
or a placebo (n=22)

From 44 subjects participated
in this study 37 completed
the study. There were no
significant differences in
baseline
characteristics, dietary intake
and physical activity between
groups.
In the treatment group, the
levels of fasting blood
glucose, HbA1c,
triglyceride, weight, BMI and
body fat mass decreased
significantly
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profile and
body
composition
in type 2
diabetic
patients.
International
Journal of
Preventive
Medicine,
3(8), 531.

7.
Vanschoonbe
ek, K.,
Thomassen,
B. J., Senden,
J. M.,
Wodzig, W.
K., & van
Loon, L. J.
(2006).
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for eight
weeks. Weight,
height, body fat
mass and systolic
and diastolic
blood pressure were
measured at baseline
and after
intervention.
The fasting blood
glucose, insulin,
HbA1c, total
cholesterol, LDL
C, HDL C, Apo
lipoprotein A I and
B were measured at
baseline
and endpoint.
The objective of this
study was to
investigate the effects
of cinnamon
supplementation on
insulin sensitivity
and/or glucose
tolerance and blood
lipid profile in
patients with type 2

A total of 25
postmenopausal
women diagnosed
with type 2 diabetes
were selected to
participate in this
study. Subjects
were assigned to a
control (n = 13) or
placebo group (n =

compared to baseline, but not
in placebo group. No
significant
differences were observed in
glycemic status indicators,
lipid
profile and anthropometric
indicators between the groups
at the
end of intervention.

 Cinnamon
Cassia 1 500
mg capsule at
breakfast,
lunch, and
dinner daily for
total of 1500
mg daily
 Time – 0, 2, and
6 weeks

 FPG levels
 Whole-body
insulin
sensitivity
 Glucose
tolerance
 Blood lipid
levels

No significant changes were
noted in whole-body indices,
fasting plasma glucose,
HbA1c, glucose tolerance, or
blood lipid profile compared
to placebo group after
cinnamon supplementation (P
> 0.05). We conclude that
cinnamon supplementation of
1.5 g/d does not improve
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Cinnamon
supplementat
ion does not
improve
glycemic
control in
postmenopau
sal type 2
diabetes
patients. The
Journal of
Nutrition,
136(4), 977980.
doi:136/4/97
7 [pii]

diabetes.

12), matched for
age, BMI, years
since diagnosis with
type 2 diabetes,
fasting blood
glucose
concentration, and
medication.
Subjects were
studied over a 6- to
7-wk period in a
double-blind,
placebo-controlled
trial. Whole-body
insulin sensitivity or
oral glucose
tolerance were
estimated by
performing an
OGTT before (wk 0)
and after 2 (wk 2)
and 6 wk (wk 6) of
supplementation.
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whole-body insulin sensitivity
or oral glucose tolerance and
does not modulate blood lipid
profile in postmenopausal
patients with type 2 diabetes.
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8. Blevins, S.
M., Leyva,
M. J., Brown,
J., Wright, J.,
Scofield, R.
H., & Aston,
C. E. (2007).
Effect of
cinnamon on
glucose and
lipid levels in
non insulindependent
type 2
diabetes.
Diabetes
Care, 30(9),
2236-2237.
doi:dc070098 [pii]

The purpose of this
study was to report
the effects of
cinnamon on lipid
levels and glucose in
the Western diabetic
population.

This trial was
 Cinnamon
randomized double
Cassia one 500
blinded placebo
mg capsule at
controlled trial with
breakfast and
57 subjects.
dinner totaling
Enrolled subjects
1g daily
received either 500  Time – 1, 2, 3
mg of cinnamon
months
cassia or placebo
(wheat flour)
capsules. Subjects
were instructed to
ingest one capsule
with breakfast and
one with dinner for 3
months.
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 FBG levels
 Lipid levels
 HbA1c
 Insulin levels

Cinnamon intake of 1g daily
for 3 months produced no
significant change in fasting
glucose, lipids, HbA1c, or
insulin levels from baseline to
1, 2, and 3 months (P > 0.05).
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9. Akilen, R.,
Tsiami, A.,
Devendra,
D., &
Robinson, N.
(2010).
Glycated
haemoglobin
and blood
pressure‐low
ering effect
of cinnamon
in
multi‐ethnic
Type 2
diabetic
patients in
the UK: a
randomized,
placebo‐contr
olled,
double‐blind
clinical trial.
Diabetic
Medicine,
27(10),
1159-1167.

The purpose of this
study was to
determine the blood
glucose lowering
effect of cinnamon on
HbA1c, blood
pressure, and lipid
profiles in people
with type 2 diabetes.

Fifty eight type 2
 Cinnamon
 HbA1c
diabetic patients (25
cassia four 500  SBP
males and 33
mg capsules
 DBP
females) treated only daily, one with
with hypoglycemic
breakfast, two
agents and with a
with lunch, and
HbA1c more than
one with dinner
7% were randomly
for 12 weeks
assigned to receive  Four 500 mg
either 2 g of
starch-filled
cinnamon or placebo placebo
daily for 12 weeks.
capsules daily,
one with
breakfast, two
with lunch, and
one with dinner
for 12 weeks
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After intervention, the mean
HbA1c was significantly
decreased (P<0.005) in the
cinnamon group (8.22% to
7.86%) compared with
placebo group (8.55% to
8.68%). Mean systolic and
diastolic blood pressures
(SBP and DBP) were also
significantly reduced
(P<0.001) after 12 weeks in
the cinnamon group (SBP:
132.6 to 129.2 mmHg and
DBP: 85.2 to 80.2 mmHg)
compared with the placebo
group (SBP: 134.5 to 134.9
mmHg and DBP: 86.8 to 86.1
mmHg). A significant
reduction in fasting plasma
glucose (FPG), waist
circumference and body mass
index (BMI) was observed at
week 12 compared to baseline
in the cinnamon group,
however, the changes were
not significant when
compared to placebo group.
There were no significant
differences in serum lipid
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profiles of total cholesterol,
triglycerides, HDL and LDL
cholesterols, neither between
nor within the groups.
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 0.5 gm
Cinnamon
(crude, ground)
after each meal,
totaling 1.5 gm
daily for 3
months
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 FBS
 RBS
 HbA1c
 Weight

10. AlYasiry, K.,
Kathum, W.,
& AlGanimi, Y.
(2014).
Evaluation of
Anti-Diabetic
Effect of
Cinnamon in
Patients with
Diabetes
Mellitus
Type Ii in
Kerbala City.
Journal of
Natural
Sciences
Research,
4(4), 43-45.

This study aimed to
determine the
hypoglycemic effect
of cinnamon in
patients with type 2
diabetes as adjuvant
therapy.

Forty male patients
with type 2 diabetes
taking oral antidiabetic drug(s)
were randomly
selected for this
quasi-experimental
trial. They were
given a crude grind
cinnamon 15
minutes after each
meal for 3 months.

11. Mang, B.,
Wolters, M.,
Schmitt, B.,
Kelb, K.,
Lichtinghage
n, R.,
Stichtenoth,
D. O., &

The aim of this trial
was to determine
whether an aqueous
cinnamon purified
extract improves
glycated
haemoglobin A1c
(HbA1c), fasting

A total of 79 patients  Cinnamon
 FPG
with diagnosed
cassia (aqueous  HbA1c
diabetes mellitus
cinnamon
 Lipid levels
type 2 not on insulin
extract) 112 mg
therapy but treated
capsules which
with oral
corresponds to 1
antidiabetics or diet
g of cinnamon
were randomly
for a total of 3 g

Results showed cinnamon had
a significant antidiabetic
effect in reduction of FBS,
RBS, & HbA1c. No
significant results were seen
in reduction of body weight
(P < 0.01).

The mean absolute and
percentage differences
between the pre- and postintervention fasting plasma
glucose level of the cinnamon
and placebo groups were
significantly different. There
was a significantly higher
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Hahn, A.
(2006).
Effects of a
cinnamon
extract on
plasma
glucose,
HbA1c, and
serum lipids
in
diabetes
mellitus type
2. European
journal of
clinical
investigation,
36(5), 340344.

plasma glucose, total
cholesterol, lowdensity lipoprotein
(LDL), high-density
lipoprotein (HDL)
and triacylglycerol
concentrations in
patients with type 2
diabetes.

assigned to take
daily for 4
either a cinnamon
months
extract or a placebo  Placebo
capsule three times a capsules
day for 4 months in
containing
a double-blind study. microcrystalline
A total of 65
cellulose only
subjects completed
the study. The
amount of aqueous
cinnamon extract
corresponded to 3 g
of cinnamon powder
per day.

reduction in the cinnamon
group (10·3%) than in the
placebo group (3·4%). No
significant intragroup or
intergroup differences were
observed regarding HbA1c,
lipid profiles or differences
between the pre- and
postintervention levels of
these variables. The decrease
in plasma glucose correlated
significantly with the baseline
concentrations, indicating that
subjects with a higher initial
plasma glucose level may
benefit more from cinnamon
intake. No adverse effects
were observed.

12.
Ziegenfuss,
T. N.,
Hofheins, J.
E., Mendel,
R. W.,
Landis, J., &
Anderson, R.
A. (2006).
Effects of a

The purpose of this
study was to
determine the effects
of supplementation
with a water-soluble
cinnamon extract
(Cinnulin PF®) on
body composition
and features of the
metabolic syndrome.

Twenty-two subjects  Cinnulin PF two  FBG
with prediabetes and 250 mg
 SBP
the metabolic
capsules BID
 Body mass
syndrome were
with breakfast
randomly assigned
and dinner daily
to supplement their
for a total of 1g
diet with either
daily (500 mg
Cinnulin PF® (500
of Cinnulin is
mg/d) or a placebo
equivalent to 10
for 12-weeks. Main
g of whole

Subjects in the Cinnulin PF®
group had significant
decreases in FBG (-8.4%:
116.3 ± 12.8 mg/dL [pre] to
106.5 ± 20.1 mg/dL [post], p
< 0.01), SBP (-3.8%: 133 ±
14 mm Hg [pre] to 128 ± 18
mm Hg [post], p < 0.001), and
increases in lean mass
(+1.1%: 53.7 ± 11.8 kg [pre]
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water-soluble
cinnamon
extract on
body
composition
and features
of the
metabolic
syndrome in
pre-diabetic
men and
women.
Journal of
the
International
Society of
Sports
Nutrition,
3(2), 45.
13.
Suppapitipor
n, S., &
Kanpaksi, N.
(2006). The
effect of
cinnamon
cassia
powder in
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outcome measures
cinnamon
were changes in
powder, i.e.,
FBG, SBP, and body 20:1 extract)
composition
 Placebo two
measured after 12250 mg
weeks of
capsules BID
supplementation.
with breakfast
and dinner daily
for a total of 1g
daily (substance
of placebo
capsule not
specified)

The objective of the
present study was to
investigate the antidiabetic effect of
cinnamon cassia
powder in type 2
diabetic patients

Sixty type 2 diabetic  Cinnamon
patients were
cassia 1.5 g
randomized either
daily (frequency
1.5 g/d of cinnamon
not specified)
cassia powder or
 Placebo 1.5 g
placebo. Both
daily(frequency
groups were in
and substance
combination with
of placebo not
their current
specified)

to 54.3 ± 11.8 kg [post], p <
0.002) compared with the
placebo group. Additionally,
within-group analyses
uncovered small, but
statistically significant
decreases in body fat (-0.7%:
37.9 ± 9.2% [pre] to 37.2 ±
8.9% [post], p < 0.02) in the
Cinnulin PF® group. No
significant changes in clinical
blood chemistries were
observed between groups over
time.

 HbA1c
 FPG
 Lipids
 LFT

After a 12-week period,
HbA1c was decreased
similarly in both groups from
8.14% to 7.76% in the
cinnamon group and from
8.06% to 7.87% in the
placebo group. This was not
found statistically
significantly different.
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type 2
diabetes
mellitus.
Journal of
the Medical
Association
of Thailand=
Chotmaihet
thangphaet,
89, S200-5.

14. Khan, R.,
Khan, Z., &
Shah, S.
(2010).
Cinnamon
may reduce
glucose, lipid
and
cholesterol
level in type
2 diabetic
individuals.

treatment
(metformin or
sulfonylurea)
according to single
blind randomized,
placebo-control trial
in a 12-week period.
Efficacy was
evaluated by HbA1c
fasting plasma
glucose, Lipid
profile, BUN,
creatinine, liver
function test and
adverse effects were
recorded.
This study was
initiated to confirm
the researcher’s
previous findings that
cinnamon intake
reduces glucose,
triglycerides and
cholesterol in type 2
diabetic individuals.

This study consisted  Ground
 FBG
of 14 type 2
cinnamon one
 Lipids
diabetics randomly
0.5 g capsule at
divided into two
breakfast,
equal groups. One
lunch, and
group was assigned
dinner for total
1.5 g cinnamon daily of 1.5 g daily
and the was assigned  Placebo of maze
1.5 g of placebo
flour one 0.5 g
daily
capsule at
breakfast,
lunch, and
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However the proportion of
patients achieving HbA1c <
or = 7% was also greater in
patients receiving cinnamon
compared with patients
receiving placebo,
nevertheless, it was not found
statistically significantly
different (35% vs 15%, x2 =
3.14, p > 0.05). No significant
intergroup differences were
observed in lipid profile,
fasting plasma glucose except
in SGOT 27.1 (8.75) to 22.1
(5) in cinnamon group and
24.08 (8.5) to 23.63 (8.88) in
the placebo group (p = 0.001).
Results show significant
reduction in FBG (P, 0.05),
triglycerides (P < 0.05) and
cholesterol levels (P < 0.05),
but no significant reduction in
HDL and LDL levels.
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Pakistan J
Nutr, 9(5),
430-433.
15. Roussel,
A. M.,
Hininger, I.,
Benaraba, R.,
Ziegenfuss,
T. N., &
Anderson, R.
A. (2009).
Antioxidant
effects of a
cinnamon
extract in
people with
impaired
fasting
glucose that
are
overweight
or obese.
Journal of
the American
College of
Nutrition,
28(1), 16-21.

37

dinner for total
of 1.5 g daily

To determine the
effects of a dried
aqueous extract of
cinnamon on
antioxidant status of
people with impaired
fasting glucose that
are overweight or
obese.

Twenty-two
 Cinnamon
 FBG
subjects, with
cinnulin PF 250  Fasting insulin
impaired fasting
mg BID for 12  Plasma
blood glucose with
weeks
malondialdehyde
BMI ranging from
 Placebo 250 mg (MDA)
25 to 45, were
BID for 12
concentrations
enrolled in a double- weeks
 Plasma
blind placebo(substance in
antioxidant
controlled trial.
placebo not
status ( evaluated
Subjects were
specified)
by FRAP assay)
divided randomly
 Blood sample
into two groups and
times – 0, 6, and
given capsules
12 weeks
containing either a
placebo or 250 mg
of an aqueous
extract of cinnamon
(Cinnulin PF) two
times per day for 12
weeks.

FRAP and plasma thiol (SH)
groups increased, while
plasma MDA levels decreased
in subjects receiving the
cinnamon extract. Effects
were larger after 12 than 6
weeks. There was also a
positive correlation (r = 0.74;
p = 0.014) between MDA and
plasma glucose.
Significant reduction was
seen in the fasting glucose of
the cinnamon group compared
to the placebo group (P <
0.05). No significant
reduction was seen in the
fasting insulin in either group.

